MERRIMACK PHARMACEUTICALS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$2.0M | −$1.7M | −$2.5M | −$2.9M | −$22.4M | −$65.6M |
| Net income | −$1.2M | −$1.5M | −$2.5M | −$3.0M | −$17.3M | −$40.5M |
| Total assets | $19.2M | $19.8M | $14.7M | $16.8M | $20.1M | $88.5M |
| Total liabilities | $441,000 | $589,000 | $562,000 | $770,000 | $2.8M | $29.7M |
| Equity | $18.7M | $19.2M | $14.2M | $16.0M | $17.3M | $58.8M |
| EPS (diluted) | $-0.08 | $-0.11 | $-0.18 | — | — | — |
| Shares out. | 14.3M | 13.4M | 13.4M | 13.4M | 13.3M | 13.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- —
- Net margin
- —
- Return on equity
- −6.3%
- Return on assets
- −6.2%
- Return on capital (ROCE)
- −10.9%
- Liabilities / assets
- 2.3%
- Debt / equity
- 0.02×
- Book value / share
- $1.32
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -42.91distress
- Accruals / assets
- 1.8%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Adar1 Partners, LpPassive (13G)Feb 22, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Andersen EricDirector | Dec 26, 2023 | Buy | 48,693 | $13.15 |
| Andersen EricDirector | Dec 7, 2023 | Buy | 76,384 | $12.85 |
| Andersen EricDirector | Nov 17, 2023 | Buy | 235 | $12.50 |
| Andersen EricDirector | Nov 14, 2023 | Buy | 39,283 | $12.50 |
| Andersen EricDirector | Nov 10, 2023 | Buy | 29,803 | $12.32 |
| Andersen EricDirector | Nov 8, 2023 | Buy | 4,783 | $12.13 |
| Crocker Gary LOfficer — See Remarks | Aug 10, 2023 | Buy | 2,000 | $12.52 |
| Andersen EricDirector | Aug 7, 2023 | Buy | 84,636 | $12.00 |
| Andersen EricDirector | Mar 21, 2023 | Buy | 127,409 | $11.52 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Shareholder vote · Regulation FD disclosureMay 10, 2024
- Regulation FD disclosureMay 9, 2024
- Delisting / listing-standard notice · Regulation FD disclosureApr 30, 2024
- Regulation FD disclosureMar 27, 2024
- Regulation FD disclosureMar 7, 2024
- Regulation FD disclosureFeb 13, 2024
- Regulation FD disclosureNov 2, 2023
- Regulation FD disclosureAug 3, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.